Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald Hoffman

Showing results (161-170 of 204) with videos related to

Pageof 21
Sort By:
Leukemia|November 26, 2022
Biological drivers of clinical phenotype in myelofibrosisJohn Mascarenhas, Hélène F E Gleitz, Helen T Chifotides, et al.
Blood|July 11, 2013
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus reportAyalew Tefferi, Francisco Cervantes, Ruben Mesa, et al.
Blood|October 25, 2022
IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasmsJohanna Melo-Cardenas, Lavanya Bezavada, Jeremy Chase Crawford, et al.
Cancer Research Communications|June 28, 2023
Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm CellsDiana Saleiro, Ewa M Kosciuczuk, Mariafausta Fischietti, et al.
JCI Insight|August 12, 2021
TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosisLilian Varricchio, Camelia Iancu-Rubin, Bhaskar Upadhyaya, et al.
Cancer Cell|July 9, 2026
Menin-dependent megakaryocyte proliferation and fibrosis in myeloproliferative neoplasmsJeremy Wen, Anitria Cotton, Rashid Mehmood, et al.
Haematologica|October 30, 2016
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosisJohn O Mascarenhas, Moshe Talpaz, Vikas Gupta, et al.
JCI Insight|March 8, 2022
Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm-blast phaseXiaoli Wang, Raajit K Rampal, Cing Siang Hu, et al.
Blood|April 18, 2013
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus projectGiovanni Barosi, Ruben Mesa, Guido Finazzi, et al.
Leukemia|October 30, 2022
An MDM2 degrader for treatment of acute leukemiasBridget K Marcellino, Xiaobao Yang, H Ümit Kaniskan, et al.
Pageof 21

Showing results (161-170 of 204) with videos related to

Sort By:
Pageof 21
Leukemia|November 26, 2022
Biological drivers of clinical phenotype in myelofibrosisJohn Mascarenhas, Hélène F E Gleitz, Helen T Chifotides, et al.
Blood|July 11, 2013
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus reportAyalew Tefferi, Francisco Cervantes, Ruben Mesa, et al.
Blood|October 25, 2022
IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasmsJohanna Melo-Cardenas, Lavanya Bezavada, Jeremy Chase Crawford, et al.
Cancer Research Communications|June 28, 2023
Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm CellsDiana Saleiro, Ewa M Kosciuczuk, Mariafausta Fischietti, et al.
JCI Insight|August 12, 2021
TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosisLilian Varricchio, Camelia Iancu-Rubin, Bhaskar Upadhyaya, et al.
Cancer Cell|July 9, 2026
Menin-dependent megakaryocyte proliferation and fibrosis in myeloproliferative neoplasmsJeremy Wen, Anitria Cotton, Rashid Mehmood, et al.
Haematologica|October 30, 2016
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosisJohn O Mascarenhas, Moshe Talpaz, Vikas Gupta, et al.
JCI Insight|March 8, 2022
Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm-blast phaseXiaoli Wang, Raajit K Rampal, Cing Siang Hu, et al.
Blood|April 18, 2013
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus projectGiovanni Barosi, Ruben Mesa, Guido Finazzi, et al.
Leukemia|October 30, 2022
An MDM2 degrader for treatment of acute leukemiasBridget K Marcellino, Xiaobao Yang, H Ümit Kaniskan, et al.
Pageof 21